文献速递肿瘤 PET/CT核素与放射性配体治疗

18F-FDG PET/CT与PERCIST标准在T-DXd治疗的HER2低表达转移性乳腺癌中的预后价值

Prognostic value of [18F]FDG PET/CT and PERCIST criteria in patients with HER2-low metastatic breast cancer treated with trastuzumab deruxtecan.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-07-01

基线SULpeak是OS、mPFS和TTT的独立预后因素,早期代谢反应与更长OS和PFS相关,联合两者可划分三个风险组。

要点

  • 基线最热病灶SULpeak是OS、mPFS和TTT的独立预后因素(p<0.05)。
  • ROC衍生截断值6将患者分为两组,SULpeak<6者预后显著更优。
  • 早期代谢反应与更长OS和PFS相关,中位PFS为9.2 vs 4.2个月(HR 2.67;95%CI 1.30-5.47)。

核心结论

  • 18F-FDG PET/CT在T-DXd治疗的HER2低表达转移性乳腺癌中提供显著预后信息。
  • 基线SULpeak和早期PERCIST代谢反应可实现有意义的危险分层。
  • 所提出的预后模型需前瞻性验证后方可临床实施。

研究设计与样本

  • 收集18F-FDG PET/CT半定量参数(SUVmax、SULpeak)及PERCIST 1.0代谢反应。
  • 采用Cox模型和Kaplan-Meier曲线分析参数与OS、mPFS和TTT的关联。

主要发现

  • 基线最热病灶SULpeak是OS、mPFS和TTT的独立预后因素(p<0.05)。
  • ROC衍生截断值6将患者分为两组,SULpeak<6与显著改善的结局相关。
  • 早期代谢反应与更长OS和PFS相关(p<0.05),中位PFS为9.2 vs 4.2个月(HR 2.67;95%CI 1.30-5.47)。
  • 联合基线SULpeak和代谢反应(完全或部分代谢反应)定义三个风险组,OS和PFS差异显著。

关键数值与推荐

  • 基线最热病灶SULpeak的ROC衍生截断值为6,SULpeak<6者结局显著更优。
  • 早期代谢反应与更长OS和PFS相关,中位PFS为9.2 vs 4.2个月(HR 2.67;95%CI 1.30-5.47)。
  • 基线SULpeak为OS、mPFS和TTT的独立预后因素(p<0.05)。

临床怎么用

  • 对接受T-DXd治疗的HER2低表达转移性乳腺癌患者,可考虑基线18F-FDG PET/CT评估SULpeak以辅助预后分层。
  • 早期PERCIST代谢反应可提示生存获益,联合基线SULpeak有助于风险分组。
  • 该预后模型需前瞻性验证后方可用于临床决策。

局限性

  • 回顾性研究设计。
  • 所提出的预后模型需前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Trastuzumab deruxtecan (T-DXd) has recently reshaped the management of HER2-low metastatic breast cancer. While pivotal trials relied on CT-based RECIST 1.1, [18F]FDG PET/CT provides high diagnostic sensitivity and valuable semi-quantitative metrics, though its role in monitoring antibody-drug conjugates remains insufficiently defined. This study assessed the prognostic value of PET-derived parameters and PERCIST criteria in patients treated with T-DXd. METHODS: This retrospective study included all HER2-low metastatic breast cancer patients treated with T-DXd between 2022 and 2025 at the Strasbourg Europe Cancer Institute (ICANS) who underwent [18F]FDG PET/CT. Semi-quantitative parameters (SUVmax, SULpeak) and metabolic response according to PERCIST 1.0 were collected. Their association with overall survival (OS), metabolic progression-free survival (mPFS) and time-to-treatment change (TTT) was analyzed using Cox models and Kaplan-Meier curves. RESULTS: Forty-three patients were included. Baseline SULpeak of the most hypermetabolic lesion was an independent prognostic factor for OS, mPFS and TTT (p < 0.05). A ROC-derived cutoff of 6 identified two prognostic groups, with SULpeak < 6 associated with significantly improved outcomes. Early metabolic response was also linked to longer OS and PFS (p< 0.05), with median PFS of 9.2 vs. 4.2 months (HR 2.67; 95% CI 1.30-5.47). Combining baseline SULpeak and metabolic response (complete or partial metabolic response) defined three risk groups with significantly different OS and PFS. CONCLUSION: [18F]FDG PET/CT provides significant prognostic information in HER2-low metastatic breast cancer treated with T-DXd. Baseline SULpeak and early PERCIST response enable meaningful risk stratification. The proposed prognostic model requires prospective validation before clinical implementation.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Frega J, Somme L, Martin T, et al. Prognostic value of [18F]FDG PET/CT and PERCIST criteria in patients with HER2-low metastatic breast cancer treated with trastuzumab deruxtecan. Eur J Nucl Med Mol Imaging. 2026. PMID: 42380496. doi:10.1007/s00259-026-08029-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。